This segment focuses on the research, development, and clinical trials of novel anti-cancer drug candidates for brain and central nervous system tumors. The primary focus is on Berubicin, an anthracycline in Phase I and II clinical trials for glioblastoma multiforme (GBM). Research and development activities include preclinical studies, manufacturing, and clinical trial management. Technologies and methodologies include drug formulation, clinical trial design, and regulatory submissions. The patient impact is significant, as GBM is an aggressive cancer with limited treatment options. Market positioning is based on addressing unmet medical needs in oncology. Future opportunities include expanding the clinical trials and potentially seeking FDA approval. Partnerships and collaborations are essential for clinical trial execution and manufacturing.